Frontlight ResearchEarly access
CompletedPhase 3
Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet
Key facts
- Who runs it
- Poitiers University Hospital
- Where
- France4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 720 people enrolled
- Started
- 25 Jan 2019
- Ended
- 28 Oct 2025
- Type of study
- Interventional
- Treatments tested
- S100B protein dosing
- Record updated
- 29 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age > 18 Years old
- Minor traumatic brain injury measured by a Glasgow score between 13 and 15
- Antiplatelet agent therapy
- Free subject without tutorship or curatorship
Who cannot take part
- Age < 18 years old
- Traumatic brain injury older than 6 hours
- Glasgow score <13
- Patient without any social security system
- Patient with renforced protection (tutorship, curatorship, …)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.
Read full original descriptionShow less
No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.
The group in the trial
- S100B protein dosingTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 December 2025